Eric has 30 years’ experience working within the Pharmaceutical Industry in research and launching of novel compounds in the therapeutic areas of psychiatry and neurodegeneration. He joined C-FIT in 2018 with the key objective of developing symbiotic partnerships with NGO’s, Government Funding Organisations, Digital/Pharma start-ups, SME’s and the larger Pharmaceutical Industry. Eric's expertise and key therapeutic areas that C-FIT are concentrating on are neurodegeneration and severe mental illness. The approach is to work on early research, i.e., bench to phase II in novel and repurposed drug technology; this also includes digital and AI therapeutics.  The key focus is that the patient is at the centre of the drug therapeutic development.